Survivin expression predicts early recurrence in early-stage breast cancer

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 2803-2808

  Yamashita, Shin Ichi ^a,b   Masuda, Yoshiko ^a   Kurizaki, Takashi ^a   Haga, Yoshio ^a   Murayama, Toshihiko ^a   Ikei, Satoshi ^a   Kamei, Mirei ^b   Takeno, Shinsuke ^b   Kawahara, Katsunobu ^b  

^a NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^b OITA UNIVERSITY   (Japan)

Author keywords

Breast cancer; Early stage; Prognostic marker; Survivin

Indexed keywords

MESSENGER RNA; SURVIVIN;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER TISSUE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HAZARD ASSESSMENT; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RNA, MESSENGER;

EID: 34547820428     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H, Margolese R, Poisson R, Shibata H and Volk H: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 52: 1551-1557, 1983.
2. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3: 46-54, 2003.
3. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry GA, Ciriello KM, Cook BP, Dufault MR, Ferguson AT, Gao Y, He TC, Hermeking H, Hiraldo SK, Hwang PM, Lopez MA, Luderer HF, Mathews B, Petroziello JM, Polyak K, Zawel K, Zhang W, Zhang X, Zhou W, Haluska FG, Jen J, Sukumar S, Landes GM, Riggins GJ, Vogelstein B and Kinzler KW: Analysis of human transcriptomes. Nat Genet 32: 387-388, 1999.
4. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T and Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58: 5071-5074, 1998.
5. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, Martin C, Font A, Barnadas A and Abad A: A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 17: 2100-2104, 1999.
6. Ikeguchi M, Hirooka Y and Kaibara N: Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma. Cancer 95: 1938-1945, 2002.
7. Ikeguchi M and Kaibara N: Survivin messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Br J Cancer 87: 883-887, 2002.
8. Rodel F, Hoffmann J, Grabenbauer GG, Papadopoulos T, Weiss C, Gunther K, Schick C, Sauer R and Rodel C: High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 178: 426-435, 2002.
9. Schultz IJ, Kiemeney LA, Witjes JA, Schalken JA, Willems JL, Swinkels DW and de Kok JB: Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 23: 3327-3331, 2003.
10. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M and Tanigawa N: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6: 127-134, 2000.
11. Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R and Clynes M: Prognostic importance of survivin in breast cancer. Br J Cancer 88: 1077-1083, 2003.
12. Bao R, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA et al: Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst 94: 522-528, 2002.
13. Aarskog NK and Vedeler CA: Real-time quantitative polymerase chain reaction. A new method that detects both the peripheral myelin protein 22 duplication in Charcot-Marie-Tooth type 1A disease and the peripheral myelin protein 22 deletion in hereditary neuropathy with liability to pressure palsies. Hum Genet 107: 494-498, 2000.
14. Nasu S, Yagihashi A, Izawa A, Saito K, Asanuma K, Nakamura M, Kobayashi D, Okazaki M and Watanabe N: Survivin mRNA expression in patients with breast cancer. Anticancer Res 22: 1839-1843, 2002.
15. Span PN, Sweep FC, Wiegerinck ET, Tjan-Heijnen VC, Manders P, Beex LV and de Kok JB: Survivin is an independent prognostic marker for risk stratification of breast cancer patients.Clin Chem 50: 1986-1993, 2004.
16. Korkola JE, DeVries S, Fridlyand J, Hwang ES, Estep AL, Chen YY, Chew KL, Dairkee SH, Jensen RM and Waldman FM: Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 63: 7167-7175, 2003.
17. Lee WY, Su WC, Lin PW, Guo HR, Chang TW and Chen HH: Expression of S100A4 and Met, potential predictors for metastasis and survival in early-stage breast cancer. Oncology 66: 429-438, 2004.
18. Barnes N, Haywood P, Flint P, Knox WF and Bundred NJ: Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer 94: 253-258, 2006.